Arrive AI Reports Third Quarter 2026 Results Highlighted by Revenue Growth and Expanded Partnerships
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Arrive AI (NASDAQ:ARAI) reported third-quarter 2026 revenue of $39,700, with expanded hospital deployments contributing to growth from a year earlier. Revenue compared with $7,450 in third-quarter 2025; net loss narrowed to $3,669,200 from $4,427,208. Operating expenses rose to $3,303,077 from $1,657,730.
For the nine months ended September 30, revenue fell to $69,325 from $98,175, while net loss widened to $24,115,833 from $10,094,444. Operating cash use increased to $9,744,919 from $5,048,431. September 30 cash was $1,052,554, alongside $965,504 in investments.
An Ottonomy agreement covers deployment of up to 50 robots and an equity investment. Arrive AI also added exploratory partnerships, established a defense division and completed its first commercial-office installation. AP3 Plus became available for shipping October 7. Management's focus is converting deployments and partnerships into recurring revenue.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major pointNine-month financing cash inflows increased to $9,692,880 from $7,772,302 a year earlier.
- Moderate pointThird-quarter revenue increased to $39,700 from $7,450 a year earlier, primarily from expanded Hancock Hospital deployment.
- Moderate pointThird-quarter net loss narrowed to $3,669,200 from $4,427,208; loss per share narrowed to $3.37 from $6.39.
- Moderate point. Forward-looking: it has not happened yet and may not happen.Ottonomy agreement provides for deployment of up to 50 ground robots at Arrive Point locations.
- Moderate pointConvertible notes payable, net, declined to $3,200,097 at September 30 from $4,144,657 at December 31, 2025.
6 minor points
- Minor pointDefense division established to explore military, defense and national security applications.
- Minor pointThird-quarter sales and marketing expenses fell to $56,687 from $107,530 a year earlier.
- Minor pointThird-quarter interest expense declined to $140,057 from $283,586 a year earlier.
- Minor pointThird-quarter loss on convertible-note conversion narrowed to $298,510 from $3,295,072 a year earlier.
- Minor pointThird-quarter realized investment gains rose to $171,538 from $46,491 a year earlier.
- Minor pointThird-quarter unrealized investment results improved to a $224,437 gain from a $76,120 loss a year earlier.
Negative
- Major pointNine-month net loss widened to $24,115,833 from $10,094,444; loss per share widened to $25.03 from $15.37.
- Major pointNine-month operating cash use increased to $9,744,919 from $5,048,431 a year earlier.
- Moderate pointNine-month revenue fell to $69,325 from $98,175 a year earlier.
- Moderate pointSeptember 30 current liabilities of $5,552,196 exceeded current assets of $2,486,852.
- Moderate pointNine-month general and administrative expenses rose to $11,232,487 from $6,739,384 a year earlier.
- Moderate pointLifeSpan Pharmacy drone-delivery proposal is a nonbinding letter of intent.
9 minor points
- Minor pointThird-quarter general and administrative expenses rose to $2,973,570 from $1,370,346 a year earlier.
- Minor pointThird-quarter research and development expenses rose to $272,820 from $179,854 a year earlier.
- Minor pointNine-month research and development expenses rose to $976,434 from $564,585 a year earlier.
- Minor pointNine-month sales and marketing expenses rose to $240,101 from $164,793 a year earlier.
- Minor pointNine-month loss on convertible-note conversion increased to $12,340,920 from $3,295,072 a year earlier.
- Minor pointNine-month interest expense increased to $655,403 from $452,843 a year earlier.
- Minor pointDebt-discount accretion expense rose to $134,137 for the quarter and $514,052 for nine months, from $88,295 and $116,033.
- Minor pointThird-quarter derivative valuation changed to a $274,164 expense from $896,266 of income a year earlier.
- Minor pointLifeSpan Pharmacy, DXC Technology, Modovolo and Purdue initiatives remain exploratory, with no revenue commitments.
News Explained
The Q3 report’s net-loss-per-share figures are restated for the 1-for-48 reverse split announced for
Sources and calculations
- Arrive AI third-quarter 2026 results release (2026-11-13)
- Arrive AI reverse-split announcement (2026-11-10)
- Reverse stock split definition (undated)
Key Figures
- Q3 revenue
- $39,700 vs. $7,450
- Third quarter 2026 vs. third quarter 2025
- Nine-month revenue
- $69,325 vs. $98,175
- Nine months ended September 30, 2026 vs. 2025
- Operating expenses
- $3,303,077 vs. $1,657,730
- Third quarter 2026 vs. third quarter 2025
- Net loss
- $3,669,200 vs. $4,427,208
- Third quarter 2026 vs. third quarter 2025
- Cash and cash equivalents
- $1,052,554
- At September 30, 2026
- Investments at fair value
- $965,504
- At September 30, 2026
- Cash used in operating activities
- $9,744,919
- Nine months ended September 30, 2026
- Potential ground robot deployment
- Up to 50 ground robots
- Ottonomy agreement; deployment at Arrive Point locations
Historical Context
-
Investment and agreement contemplated potential deployment of 50 ground robots across partner locations.
-
Parkway expansion added scheduled and on-demand specimen runs to the existing hospital delivery system.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
autonomous mobile robots (amrs) technical
edge computing technical
chain of custody technical
convertible notes financial
derivative liabilities financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
INDIANAPOLIS, IN / ACCESS Newswire / November 13, 2026 / Arrive AI (NASDAQ:ARAI), a physical AI and autonomous logistics infrastructure company enabling drones, autonomous mobile robots (AMRs), autonomous vehicles (AVs) and human couriers to securely exchange goods, today announced financial results for the third quarter ended September 30, 2026.
Management will host a conference call and webcast today at 8:30 a.m. Eastern Time to discuss the results. Access details are below.
"Third quarter revenue grew from a year ago as Hancock Regional Hospital expanded its use of our Arrive Points™, and that kind of repeat adoption by an existing customer is how we expect this network to expand," said Dan O'Toole, Founder and CEO of Arrive AI. "During the quarter and the weeks since, we made AP3 Plus available for shipping, completed our first installations at a commercial office building, and added partners in manufacturing, pharmacy, and drone delivery. We also streamlined our cost structure to focus resources on our commercial priorities. Revenue is still at an early stage, and our focus is now on turning these deployments and partnerships into recurring revenue. We are receiving inbound inquiries at a very robust level which we think will translate into substantial results as we move forward."
Operational Highlights & Recent Developments
- Hancock Regional Hospital: Added an Arrive Point™ at the Parkway Building, expanding the existing deployment and contributing to sequential revenue growth in the third quarter.
- Ottonomy Robots: Announced an agreement to deploy up to 50 ground robots at Arrive Point™ locations, and a strategic equity investment in Ottonomy to support integration.
- AP3 Plus Launch: Available for shipping since October 7, adding edge computing and on-board vision for package detection and chain of custody tracking.
- Partnerships: Signed a nonbinding letter of intent with LifeSpan Pharmacy to explore a drone pharmacy delivery program, partnered with DXC Technology to bring Arrive Point™ technology into large manufacturing campuses, partnered with Modovolo on automated drone delivery, and began early discussions with Purdue University about testing Arrive Point™ technology with robot platforms on campus. These initiatives remain exploratory and carry no revenue commitments.
- Defense Division: Established under Chief Strategy Officer Neerav Shah to explore military, defense and national security applications, extending the potential market for Arrive AI's core technology while maintaining its focus on commercial delivery.
- Commercial Office Deployment: Installed two AP3+ Arrive Point™ units in Central Indiana, the first Arrive Point™ installation in a commercial office building.
Q3 2026 Financial Highlights
- Revenue totaled
$39,700 for the third quarter, compared with$7,450 in the third quarter of 2025, primarily due to an expanded deployment with Hancock Hospital. - Total operating expenses were
$3.3 million for the third quarter, compared with$1.7 million in the third quarter of 2025. General and administrative expenses were$3.0 million , compared with$1.4 million . - Net loss was
$3.7 million for the third quarter, compared with$4.4 million in the third quarter of 2025. - Cash and cash equivalents were
$1.1 million and investments at fair value were$1.0 million at September 30, 2026, compared with cash and cash equivalents of$2.1 million and no investments at December 31, 2025.
Earnings Call Details
- Title: Arrive AI Inc. Q3 2026 Earnings Call
- Date: November 13, 2026
- Time: 8:30 AM EDT (Live Event)
- Webcast Link: https://edge.media-server.com/mmc/p/2bb2cpjt
A replay of the call will be available after the event on Arrive AI's website at investors.arriveai.com.
About Arrive AI
Arrive AI (NASDAQ:ARAI) is building the infrastructure for autonomous logistics through a network of intelligent delivery endpoints that enable secure, asynchronous exchange of goods. The company's platform supports drones, ground robotics, and human couriers, solving the "last inch of the last-mile" challenge across logistics, healthcare, and enterprise delivery.
Forward-Looking Statements
This news release and statements of Arrive AI's management in connection with this release or related events may contain "forward-looking statements" within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. Forward-looking statements relate to future events and expected business and financial performance and often include words such as "expects," "anticipates," "intends," "plans," "believes," "potential," "will," "should," "could," "would," "optimistic," or "may," and similar expressions. These statements are based on information available as of the date of this release and reflect management's current views and assumptions. They are not guarantees of future performance and involve known and unknown risks, uncertainties, and other factors that may be beyond the company's control. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this release. Potential investors should review Arrive AI's Registration Statement and other filings, including risk factors, available at the U.S. Securities and Exchange Commission website at www.sec.gov. Arrive AI undertakes no obligation to update forward-looking statements to reflect events or circumstances after the date of this release, except as required by law.
Media Contact
Tasha Jones, Marketing Communications Manager, Arrive AI, media@arriveai.com
Investor Contact
Alliance Advisors IR, ARAI.IR@allianceadvisors.com
ARRIVE AI INC.
CONDENSED STATEMENTS OF OPERATIONS (Unaudited)
| Three Months Ended Sept 30, 2026 | Three Months Ended Sept 30, 2025 | Nine Months Ended Sept 30, 2026 | Nine Months Ended Sept 30, 2025 | |||||||||||||
Revenue | $ | 39,700 | $ | 7,450 | $ | 69,325 | $ | 98,175 | ||||||||
General and administrative | 2,973,570 | 1,370,346 | 11,232,487 | 6,739,384 | ||||||||||||
Research and development | 272,820 | 179,854 | 976,434 | 564,585 | ||||||||||||
Sales and marketing | 56,687 | 107,530 | 240,101 | 164,793 | ||||||||||||
Total operating expenses | 3,303,077 | 1,657,730 | 12,449,022 | 7,468,762 | ||||||||||||
Interest expense | (140,057 | ) | (283,586 | ) | (655,403 | ) | (452,843 | ) | ||||||||
Other income | 45,070 | 23,388 | 373,738 | 83,454 | ||||||||||||
Change in fair value of derivative liabilities | (274,164 | ) | 896,266 | 948,658 | 1,086,266 | |||||||||||
Accretion of debt discount | (134,137 | ) | (88,295 | ) | (514,052 | ) | (116,033 | ) | ||||||||
Loss on conversion of convertible notes payable | (298,510 | ) | (3,295,072 | ) | (12,340,920 | ) | (3,295,072 | ) | ||||||||
Realized gain on investments | 171,538 | 46,491 | 494,356 | 46,491 | ||||||||||||
Unrealized gain (loss) on investments | 224,437 | (76,120 | ) | (36,539 | ) | (76,120 | ) | |||||||||
Loss on disposal of fixed assets | - | - | (5,974 | ) | - | |||||||||||
Total other income (expenses) | (405,823 | ) | (2,776,928 | ) | (11,736,136 | ) | (2,723,857 | ) | ||||||||
Net loss before taxes | (3,669,200 | ) | (4,427,208 | ) | (24,115,833 | ) | (10,094,444 | ) | ||||||||
Provision for income taxes | - | - | - | - | ||||||||||||
Net loss | $ | (3,669,200 | ) | $ | (4,427,208 | ) | $ | (24,115,833 | ) | $ | (10,094,444 | ) | ||||
Net loss per share, basic and diluted (restated for the 1-for-48 reverse split) | $ | (3.37 | ) | $ | (6.39 | ) | $ | (25.03 | ) | $ | (15.37 | ) | ||||
Weighted-average common shares outstanding, basic and diluted | 1,090,114 | 692,615 | 963,385 | 656,565 | ||||||||||||
CONDENSED BALANCE SHEETS (Unaudited)
| September 30, 2026 (Unaudited) | December 31, 2025 | |||||||
Cash and cash equivalents | $ | 1,052,554 | $ | 2,104,004 | ||||
Investments at fair value | 965,504 | - | ||||||
Accounts receivable, net of allowance | 31,805 | 4,975 | ||||||
Inventory | 49,655 | - | ||||||
Prepaid expenses | 375,009 | 189,878 | ||||||
Other current assets | 12,325 | 12,325 | ||||||
Total current assets | 2,486,852 | 2,311,182 | ||||||
Property and equipment, net | 826,185 | 514,684 | ||||||
Right of use assets, operating leases | 1,827,590 | 2,117,284 | ||||||
Patents, net | 270,547 | 272,097 | ||||||
Deferred offering costs | 3,453,767 | 5,650,185 | ||||||
Other assets | 317,226 | 65,633 | ||||||
TOTAL ASSETS | $ | 9,182,167 | $ | 10,931,065 | ||||
Accounts payable | 175,820 | 183,993 | ||||||
Accrued expenses | 1,210,170 | 538,234 | ||||||
Operating lease liability, current | 427,472 | 392,950 | ||||||
Derivative liabilities | 524,977 | 1,460,000 | ||||||
Convertible note payable, net of discount and issuance costs | 3,200,097 | 4,144,657 | ||||||
Note payable, current | 13,660 | 9,140 | ||||||
Total current liabilities | 5,552,196 | 6,728,974 | ||||||
Operating lease liability, long term | 1,403,075 | 1,725,073 | ||||||
Note payables, net of current portion | 28,244 | 1,418 | ||||||
Total liabilities | 6,983,515 | 8,455,465 | ||||||
Common stock | 11,066 | 6,841 | ||||||
Additional paid-in capital | 55,050,358 | 31,215,698 | ||||||
Accumulated deficit | (52,862,772 | ) | (28,746,939 | ) | ||||
Total stockholders' equity | 2,198,652 | 2,475,600 | ||||||
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $ | 9,182,167 | $ | 10,931,065 | ||||
CONDENSED STATEMENTS OF CASH FLOWS (summary, nine months, Unaudited)
| Nine Months Ended Sept 30, 2026 | Nine Months Ended Sept 30, 2025 | |||||||
Net cash used in operating activities | $ | (9,744,919 | ) | $ | (5,048,431 | ) | ||
Net cash used in investing activities | (999,411 | ) | (2,036,474 | ) | ||||
Net cash provided by financing activities | 9,692,880 | 7,772,302 | ||||||
Net increase (decrease) in cash and cash equivalents | (1,051,450 | ) | 687,397 | |||||
Cash and cash equivalents, beginning of period | 2,104,004 | 129,318 | ||||||
Cash and cash equivalents, end of period | $ | 1,052,554 | $ | 816,715 | ||||
SOURCE: Arrive AI Inc.
View the original press release on ACCESS Newswire
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were Arrive AI's third-quarter 2026 revenue and net loss?
Arrive AI reported revenue of $39,700 and a net loss of $3,669,200 for the quarter ended September 30, 2026. Revenue increased from $7,450, while net loss narrowed from $4,427,208 in the year-earlier quarter. Basic and diluted loss per share was $3.37, compared with $6.39.
How much cash did Arrive AI have at September 30, 2026?
Arrive AI had $1,052,554 in cash and cash equivalents and $965,504 in investments at fair value at September 30, 2026. At December 31, 2025, cash and cash equivalents were $2,104,004, with no investments at fair value.
Do Arrive AI's new partnerships include committed revenue?
The LifeSpan Pharmacy, DXC Technology, Modovolo and Purdue initiatives are exploratory and carry no revenue commitments. LifeSpan signed a nonbinding letter of intent to explore drone pharmacy delivery. DXC's partnership concerns manufacturing campuses, Modovolo's concerns automated drone delivery, and Purdue discussions concern campus testing with robot platforms.